Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of AZD5055 on Nintedanib PK in Healthy Participants
NCT05644600Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- May 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AZD5055 in idiopathic pulmonary fibrosis (IPF), sponsored by AstraZeneca. Primary endpoints: Maximum observed plasma drug concentration of Nintedanib at Day 9, Area under plasma concentration time curve from zero to infinity of Nintedanib at Day 9 and 1 more. Started May 2023; status: terminated.
02
Drugs
AZD5055
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05644600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05644600.